Skip to main content

Table 6 Association of HCC aggressiveness index with sociodemographic and clinical characteristics and genotype of HCC cases

From: Association of IL-10 and TNF-α polymorphisms with risk and aggressiveness of hepatocellular carcinoma in patients with HCV-related cirrhosis

  AGI Test of significance
  A B C
Age/years, mean ± SD 54.64 ± 4.44 57.74 ± 4.98 56.18 ± 4.15 F = 2.66
P = 0.08
Sex, n (%)
 Male 13 (59.1) 15 (65.2) 15 (53.6) χ2 = 0.708
P = 0.702
 Female 9 (40.9) 8 (34.8) 13 (46.4)
Albumin (g/dl), mean ± SD 3.36 ± 0.62 3.23 ± 0.71 3.28 ± 0.46 F = 0.280
P = 0.757
Bilirubin (mg/dl), median (IQR) 1.1 (0.90-1.7) 1.68 (0.80–2.4) 1.20 (0.825–1.5) KW
P = 0.514
WBCS, mean ± SD 5.25 ± 1.89 4.40 ± 1.21 4.72 ± 2.28 F = 1.15
P = 0.32
HB (g/dl), mean ± SD 11.88 ± 1.43 10.91 ± 1.56 11.24 ± 1.84 F = 1.15
P = 0.32
Platelet ˟103, mean ± SD 85.09 ± 29.89 116.09 ± 56.5 101.25 ± 38.8 F = 2.92
P = 0.061
ALT (u/l), median (IQR) 38.0 (27.0–43.0) 36.0 (32.0–55.0) 33.0 (29.25–65.75) KW
P = 0.482
AFP (ng/dl), median (IQR) 190 (83.0–536.0)a 83.0 (27.0–340.0) 67.0 (32.0–106.25)a KW
P = 0.013*
AST(u/l), median (IQR) 56.0 (47.0–88.0) 69.0 (66.0–89.0) 71.0 (53.0–98.0) KW
P = 0.09
INR, mean ± SD 1.36 ± 0.13 1.41 ± 0.29 1.31 ± 0.15 F = 1.71
P = 0.189
DM, n (%) 8 (36.4) 9 (39.1) 14 (50.0) P = 0.58
Hypertension, n (%) 6 (27.3) 6 (26.1) 7 (25.0) P = 0.98
IL-10 genotypes
 TT/AA 2 (9.1)a 6 (26.1)b 21 (75.0)a,b MC
P < 0.001*
 CT/CA 8 (36.4) 9 (39.1) 4 (14.3)
 CC/CC 12 (54.5) 8 (34.8) 3 (10.7)
TNF-ɑ genotypes
 GG 0 (0.0)a,b 9 (39.1)a,c 26 (92.9)b,c MC
P < 0.001*
 GA 12 (54.5) 8 (34.8) 2 (7.1)
 AA 10 (45.5) 6 (26.1) 0 (0.0)
  1. MC Monte Carlo test, KW Kruskal-Wallis test, F one-way ANOVA test
  2. * means statistically significant
  3. a significance with group a
  4. b significance with group b
  5. c significance with group c
  6. ab significance with group a, b
  7. bc significance with group b, c